Clinical Study of Cisplatin Combined with Late-course Accelerated Hyperfractionated Radiotherapy for Esophageal Carcinoma

Objective:To evaluate the efficacy of cisplatin combined with late-course accelerated hyperfractionated radiotherapy for esophageal carcinoma.Method:Two-hundred and eight-four cases with esophageal carcinomas were randomized into two groups(the chemoradiotherapy group and radiotherapy alone group).Each group consists 142 cases.6MVX-ray was employed externally.Conventional radiotherapy of 2Gy per day was employed during the former two thirds course to a total dose of 40Gy,then followed by accelerated hyperfractionated(twice per day,1.5Gy at one time,6-hour interval,27Gy for 9 days,a total dose of 67Gy,20mg cisplatin ivgtt used from dl to d5).Results:1-and 2-year survival rate in the combined group and the single group were 86.6%,70.4% and 73.2%,50.7% respectively(P0.05),and 3-and 4-year survival rate were 48.5%,41.5% and 40.8%,34.5% respectively(P0.05).Conclusions:Cisplatin plus late-course accelerated hyperfractionated radiotherapy for esophageal carcinoma could possiblly improve the short term survival rate with well tolerated side effects.